Latest News

– Trial Stopped Early Due to Positive Results at Planned Interim Analysis – – Data Intended to Support Global Registrations and Convert Accelerated to Regular Approval in U.S.  San Francisco, CA (UroToday.com) — Astellas Pharma Inc. and Seattle Genetics, Inc. announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv) met its primary endpoint of overall […]

We sought to assess the impact of Affordable Care Act Dependent Care Expansion (ACA-DCE), which allowed dependent coverage for adults aged 19-25, and Medicaid expansion on outcomes for men with testicular cancer.

The study investigated the expression and the clinicopathological significance of p53, p27, Ki-67, E-cadherin, and HER2 in upper urinary tract urothelial carcinomas (UTUC) from Tunisian patients. We performed a retrospective study of 66 UTUC.

To assess the value of diffusion-weighted magnetic resonance imaging (DW-MRI) and contrast-enhanced MRI (CE-MRI) for differentiation between benign and malignant solid renal masses, renal cell carcinoma (RCC) subtypes, oncocytomas, and lipid-poor angiomyolipomas (LP-AML).

To validate a simulation environment for virtual planning of percutaneous cryoablation of renal tumors. Prospectively collected data from 19 MR-guided procedures were used for validation of the simulation model.

Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear. To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients.

The BRG1/BRM associated factors (BAF) complex is a chromatin remodeling SWI/SNF which is mutated in 20% of cancers. This complex has many interchangeable subunits which may have oncogenic or tumor suppressor activity in a context-dependent manner.

Focal therapy (FT) became a frequently discussed treatment strategy of localized prostate cancer (PCa), but the acceptance and evaluation of FT by practicing urologists is still unclear. A 25-item anonymized online questionnaire (SurveyMonkey®) was compiled by the German Society of Residents in Urology (GesRU) Academics prostate cancer working group and sent to the members of […]

Clinical management of bladder carcinomas (BC) remains a major challenge and demands comprehensive multi-omics analysis for better stratification of the disease. Identification of patients on risk requires identification of signatures predicting prognosis risk of the patients.

Current first-line treatment options in patients with metastatic urothelial carcinoma (mUC) unfit to receive cisplatin-containing chemotherapy include PD-1/L1 inhibitors and carboplatin-containing chemotherapy.